Si be pre nlim ab for children with IgA nephropathy
Part of Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests a new medicine called sibeprenlimab for children and teens with IgA nephropathy, a kidney disease. The medicine may reduce protein in the urine and help protect kidney function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with IgA nephropathy by a kidney biopsy.
- You have been on a stable dose of blood pressure medicines called ACE inhibitors or ARBs for at least 12 weeks.
- If you take an SGLT2 inhibitor (a type of diabetes/kidney medicine), you have been on it for at least 12 weeks.
- Your urine protein level is high, measured by a urine test.
- Your kidney function is at a certain level, checked by a blood test.
- You do not have other kidney diseases or conditions that are not related to IgA nephropathy.
- Your immunoglobulin G (IgG) level is normal, checked by a blood test.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a drug called sibeprenlimab to see how it affects kidney tissue in people with IgA nephropathy (IgAN), a condition where antibodies build up in the kidneys. It may help protect your kidneys if your disease is still active.
This trial enrolls teens and adults with biopsy-proven IgA nephropathy to help doctors learn whether a specific care approach works better for high-quality treatment. It is meant for people whose IgA kidney disease is the primary form (not caused by another illness).
This study tests a new medicine called CM313 for people with IgA nephropathy, a kidney disease. The goal is to see if it can help reduce protein in the urine and protect kidney function.
This study tests an investigational drug called SCTC21C for people with IgA nephropathy, a kidney disease caused by abnormal antibodies. The drug aims to target and reduce these harmful antibodies, which may help slow kidney damage.
This trial tests a new medicine called NM8074 for people with IgA nephropathy (a kidney disease). The medicine is given as an infusion and aims to slow down the damage to your kidneys. If you have this condition and meet the health requirements, the trial might help you manage your kidney health.
This trial studies sibeprenlimab to see if it can improve IgA nephropathy, a kidney inflammation condition. You may be able to join if you finished a previous related Otsuka study without major safety problems and your doctor thinks you could benefit.
Hear when a new IgA Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.